ALX Oncology Holdings Inc.
ALXO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $17 | $18 | $24 | $24 |
| G&A Expenses | $5 | $5 | $8 | $7 |
| SG&A Expenses | $5 | $5 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $0 | $0 |
| Operating Expenses | $23 | $27 | $32 | $31 |
| Operating Income | -$23 | -$27 | -$32 | -$31 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $1 | $1 |
| Pre-Tax Income | -$22 | -$26 | -$31 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$26 | -$31 | -$29 |
| % Margin | – | – | – | – |
| EPS | -0.41 | -0.49 | -0.58 | -0.55 |
| % Growth | 16.3% | 15.5% | -5.5% | – |
| EPS Diluted | -0.41 | -0.49 | -0.58 | -0.55 |
| Weighted Avg Shares Out | 54 | 53 | 53 | 53 |
| Weighted Avg Shares Out Dil | 54 | 53 | 53 | 53 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$25 | -$30 | -$29 |
| % Margin | – | – | – | – |